RS52351B - Etilamid mezilat 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilne kiseline, njihovi hidrati i polimorfi, i formulacije koje obuhvataju ove oblike - Google Patents

Etilamid mezilat 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilne kiseline, njihovi hidrati i polimorfi, i formulacije koje obuhvataju ove oblike

Info

Publication number
RS52351B
RS52351B RS20120263A RSP20120263A RS52351B RS 52351 B RS52351 B RS 52351B RS 20120263 A RS20120263 A RS 20120263A RS P20120263 A RSP20120263 A RS P20120263A RS 52351 B RS52351 B RS 52351B
Authority
RS
Serbia
Prior art keywords
phenyl
ylmethyl
dihydroxy
isopropyl
isoxazole
Prior art date
Application number
RS20120263A
Other languages
English (en)
Serbian (sr)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis (R & D) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52351(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis (R & D) Ltd filed Critical Novartis Ag
Publication of RS52351B publication Critical patent/RS52351B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
RS20120263A 2007-03-01 2008-02-28 Etilamid mezilat 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilne kiseline, njihovi hidrati i polimorfi, i formulacije koje obuhvataju ove oblike RS52351B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
RS52351B true RS52351B (sr) 2012-12-31

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120263A RS52351B (sr) 2007-03-01 2008-02-28 Etilamid mezilat 5-(2,4-dihidroksi-5-izopropil-fenil)-4-(4-morfolin-4-ilmetil-fenil)-izoksazol-3-karboksilne kiseline, njihovi hidrati i polimorfi, i formulacije koje obuhvataju ove oblike

Country Status (40)

Country Link
US (3) US8163747B2 (enExample)
EP (2) EP2131845B1 (enExample)
JP (1) JP2010520176A (enExample)
KR (1) KR20090122218A (enExample)
CN (2) CN102302500A (enExample)
AR (1) AR065519A1 (enExample)
AT (1) ATE552836T1 (enExample)
AU (1) AU2008220800B2 (enExample)
BR (1) BRPI0807992A2 (enExample)
CA (1) CA2678043A1 (enExample)
CL (1) CL2008000618A1 (enExample)
CO (1) CO6210828A2 (enExample)
CR (1) CR10989A (enExample)
CY (1) CY1113805T1 (enExample)
DK (1) DK2131845T3 (enExample)
DO (1) DOP2009000209A (enExample)
EA (1) EA017075B1 (enExample)
EC (1) ECSP099602A (enExample)
ES (1) ES2384906T3 (enExample)
GE (1) GEP20115309B (enExample)
GT (1) GT200900236A (enExample)
HR (1) HRP20120535T1 (enExample)
IL (1) IL200401A0 (enExample)
MA (1) MA31204B1 (enExample)
MX (1) MX2009009233A (enExample)
NI (1) NI200900161A (enExample)
NZ (1) NZ578854A (enExample)
PA (1) PA8771101A1 (enExample)
PE (1) PE20090166A1 (enExample)
PL (1) PL2131845T3 (enExample)
PT (1) PT2131845E (enExample)
RS (1) RS52351B (enExample)
SI (1) SI2131845T1 (enExample)
SM (1) SMAP200900080A (enExample)
TN (1) TN2009000357A1 (enExample)
TW (1) TW200844102A (enExample)
UA (1) UA101950C2 (enExample)
UY (1) UY30943A1 (enExample)
WO (1) WO2008104595A1 (enExample)
ZA (1) ZA200905417B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8309578B2 (en) 2008-11-25 2012-11-13 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2011089234A2 (en) * 2010-01-21 2011-07-28 Aprea Ab Method and composition
CN102753546A (zh) * 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
HRP20120535T1 (hr) 2012-07-31
ATE552836T1 (de) 2012-04-15
EP2545921A2 (en) 2013-01-16
GT200900236A (es) 2011-09-14
TN2009000357A1 (en) 2010-12-31
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
CY1113805T1 (el) 2016-07-27
MA31204B1 (fr) 2010-02-01
EA017075B1 (ru) 2012-09-28
EP2131845B1 (en) 2012-04-11
CO6210828A2 (es) 2010-10-20
KR20090122218A (ko) 2009-11-26
AR065519A1 (es) 2009-06-10
SI2131845T1 (sl) 2013-02-28
CA2678043A1 (en) 2008-09-04
US20130296556A1 (en) 2013-11-07
AU2008220800A1 (en) 2008-09-04
JP2010520176A (ja) 2010-06-10
PL2131845T3 (pl) 2012-09-28
UA101950C2 (ru) 2013-05-27
ES2384906T3 (es) 2012-07-13
TW200844102A (en) 2008-11-16
HK1139073A1 (en) 2010-09-10
NI200900161A (es) 2010-07-27
UY30943A1 (es) 2008-10-31
PT2131845E (pt) 2012-07-10
PE20090166A1 (es) 2009-03-14
US8163747B2 (en) 2012-04-24
EA200901141A1 (ru) 2010-04-30
ECSP099602A (es) 2009-12-28
BRPI0807992A2 (pt) 2014-06-17
NZ578854A (en) 2012-03-30
CN102302500A (zh) 2012-01-04
DOP2009000209A (es) 2009-09-15
MX2009009233A (es) 2010-06-02
GEP20115309B (en) 2011-10-25
CL2008000618A1 (es) 2008-09-12
SMAP200900080A (it) 2010-01-19
PA8771101A1 (es) 2009-02-09
IL200401A0 (en) 2010-04-29
US20120172592A1 (en) 2012-07-05
EP2131845A1 (en) 2009-12-16
US8487095B2 (en) 2013-07-16
US20100093732A1 (en) 2010-04-15
CN101636162A (zh) 2010-01-27
WO2008104595A1 (en) 2008-09-04
ZA200905417B (en) 2010-05-26
AU2008220800B2 (en) 2012-02-16
CR10989A (es) 2010-03-01

Similar Documents

Publication Publication Date Title
AU2005274339B2 (en) Dihydropteridinone infusion solution having a long shelf life
ES2428746T3 (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxilo con derivados de ácidos aminonicotínicos como inhibidores de DHODH
AU2008220800B2 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
BRPI0719650A2 (pt) Derivados de azabiciclo-octano, método de fabricação deles e usos dos mesmos como inibidores de dipeptidil peptidade iv
CA2987879A1 (en) Aqueous drug
CN102807575B (zh) 3-芳基-5-噻吩基-5H-噻唑并[3,2-a]嘧啶类衍生物及其应用
KR100976097B1 (ko) 이오프로마이드의 z 이성체를 선택적으로 결정화하는 방법
CA3067271A1 (en) Crystalline forms of ponatinib hydrochloride
ES2358884T3 (es) Procedimiento para la preparación de una inyección acuosa isotónica de ropivacaína.
DK1706383T3 (en) Amine salt of carbostyril derivative useful for the treatment of, among other things, gastric ulcer
HK1139073B (en) 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide mesylate, hydrates and polymorphs thereof, and formulations comprising these forms
AU701154B2 (en) Pyrrolidinyl methyl indole salt
JP7425482B2 (ja) イソキノリンスルホンアミドの新規な形態
IE990387A1 (en) A ranitidine base water adduct
JP5709499B2 (ja) リボフラビン又はその誘導体の安定化
JPH0315632B2 (enExample)